Prnewswire·2026-01-08 21:05Core Insights - ADC Therapeutics reported preliminary unaudited net product revenue of approximately $22 million for Q4 2025 and $73 million for the full year 2025, showing growth from $69.3 million in 2024 [1][3] - The company ended 2025 with cash and cash equivalents of approximately $261 million, providing a cash runway expected to last at least until 2028 [1][3] - Anticipated near-term catalysts include complete enrollment in the LOTIS-7 trial in the first half of 2026 and topline data from the LOTIS-5 Phase 3 trial in Q2 2026 [1][5] Financial Performance - ZYNLONTA net product revenue for 2025 is expected to be approximately $73 million, an increase from $69.3 million in 2024 [3] - Q4 2025 net product revenue is projected to be around $22 million, compared to $16.4 million in Q4 2024, reflecting variability in customer ordering [3] - The underlying demand for ZYNLONTA in the current 3L/3L+ DLBCL indication remained stable year-over-year [3] Clinical Developments - Updated data from the LOTIS-7 trial showed an 89.8% best overall response rate and a 77.6% complete response rate among 49 efficacy evaluable patients [4] - Enrollment in the LOTIS-7 trial is ongoing, with complete enrollment of approximately 100 patients expected in the first half of 2026 [4] - LOTIS-5 topline results are anticipated in Q2 2026, with full results expected by the end of 2026 [5] Regulatory and Strategic Outlook - Assuming positive results from ongoing trials, the company anticipates potential compendia inclusion for LOTIS-5 and LOTIS-7 in the first half of 2027, followed by regulatory approvals [2][5] - Investigator-initiated trials of ZYNLONTA in indolent lymphomas are ongoing, with promising initial data expected to be published by the end of 2026 [6] - The company has completed IND-enabling activities for a PSMA-targeting ADC and is exploring partnership opportunities [7][8]